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ABSTRACT
Neonatal hypoxic-ischemic encephalopathy (NHIE) is a dramatic perinatal complication, associated
with poor neurological prognosis despite neuroprotection by therapeutic hypothermia, in the
absence of an available curative therapy. We evaluated and compared ready-to-use human umbili-
cal cord blood cells (HUCBC) and bankable but allogeneic endothelial progenitors (ECFC) as cell
therapy candidate for NHIE. We compared beneﬁts of HUCBC and ECFC transplantation 48 hours
after injury in male rat NHIE model, based on the Rice-Vannucci approach. Based on behavioral
tests, immune-histological assessment and metabolic imaging of brain perfusion using single pho-
ton emission computed tomography (SPECT), HUCBC, or ECFC administration provided equally
early and sustained functional beneﬁts, up to 8 weeks after injury. These results were associated
with total normalization of injured hemisphere cerebral blood ﬂow assessed by SPECT/CT imaging.
In conclusion, even if ECFC represent an efﬁcient candidate, HUCBC autologous criteria and easier avail-
ability make them the ideal candidate for hypoxic-ischemic cell therapy. STEM CELLS TRANSLATIONAL
MEDICINE 2017;6:1987–1996
SIGNIFICANCE STATEMENT
Neonatal hypoxic ischemic encephalopathy is a dramatic perinatal complication. Neurological
and neurosensory sequelae are frequent in survivors, including motor or learning disabilities,
cerebral palsy, or epilepsy. Facing the absence of effective curative therapy, many hopes have
been credited in cell therapy strategies. Based on behavioral tests, immune-histological assess-
ment and metabolic imaging of brain perfusion using single photon emission computed tomog-
raphy, we report in this work that cell transplantation of both human umbilical cord blood cells
and endothelial progenitors provided equally early and sustained functional benefits, up to
adulthood.
INTRODUCTION
Neonatal hypoxic-ischemic encephalopathy (NHIE)
is a dramatic consequence of perinatal asphyxia,
causing neonatal mortality and severe morbidity
including cerebral palsy, sensory sequelae, epi-
lepsy, cognitive impairment, and learning disabil-
ities. Cerebral hypoxia-ischemia (HI) induces a
cascade of events including inﬂammation, excito-
toxic amino acids release, and oxidative stress,
leading to cell and neuronal apoptosis and tissue
necrosis. Therapeutic hypothermia proposed in
severe NHIE has shown beneﬁcial, but limited
neuroprotective effects [1–3]. Additional thera-
peutic strategies are under investigation.
Experimental studies using autologous or het-
erologous human umbilical cord blood cells
(HUCBC) or mesenchymal stem cells demon-
strated neuroprotective effects in NHIE models
[4–7]. The mechanisms of their effects have been
shown to involve paracrine and growth factors
release, rather than engraftment and direct repair
mechanisms [4–6]. Long-term consequences of
such treatment on brain metabolism and func-
tional neurologic abilities have been little investi-
gated [8].
The neuroprotective effects of HUCBC may be
linked to endothelial progenitor cells. These cells
are a small fraction of the blood mononuclear cell
population [9, 10] and play a critical role in
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CORD BLOOD
vascular repair and tissue recovery by promoting the formation of
new blood vessels in conditions of tissue ischemia. Endothelial
colony-forming cells (ECFC) are a homogeneous, well-
characterized population of endothelial progenitor cells with high
proliferating capacity. They are considered to be relevant endothe-
lial progenitors due to their speciﬁc vasculogenic activity [11–13].
We and others have previously reported protective and regenera-
tive effects of ECFC administration in an adult model of cerebral
ischemia [14, 15]. To date, the effects of ECFC administration have
not been investigated in models of NHIE. Data from preclinical
studies are still needed and are essential to design and support
future clinical trials aiming to investigate the neuroprotective
effects of autologous administration of cord blood cells in infants
with severe NHIE. Indeed, the high concentration of active cells
(progenitor, immune, and stem cells), the ease of access and well-
known cell processing techniques make cord blood a potential
neuroprotective therapy for infants suffering NHIE [4, 5, 7, 16].
The aim of this study was to evaluate and compare the effects
of HUCBC and ECFC administration after neonatal cerebral HI in
the rat. Histologic, single photon emission computed tomography
(SPECT) imaging used for brain metabolism and perfusion activity,
and neurologic functions were assessed during the neonatal
period and in adulthood.
MATERIALS AND METHODS
The experimental protocol is presented in Figure 1.
Animal Care and Surgical Procedure of Cerebral HI
This study was approved by the local institutional Animal Care
and Use Committee (CE14, Aix-Marseille Universite, agreement 3-
17012013) and was conducted according to the ofﬁcial edict pre-
sented by the French Ministry of Agriculture (Paris, France) and
the recommendations of the Helsinki Declaration. The experi-
ments were conducted in an authorized laboratory (C13-055-20).
Pregnant Sprague-Dawley rats (Charles Rivers, l’Arbresle, France,
http://www.criver.com n5 23) were housed in a room with a 12-
hour light/dark cycle at a controlled temperature of 228C. They
had access to food and water ad libitum. After each delivery, litter
sizes were adjusted to 10 pups per litter. Neonatal rats were car-
ried by their mothers until they were weaned (day 21). They were
then housed four per cage on standard rat chow (Safe-UAR).
Only male rats (n5 122) were used in our study to avoid bias
due to gender differences [17]. Each neurological, histological, and
isotopic imaging assessment was performed by a single investiga-
tor blinded to the experimental groups.
A variation of the Rice-Vannucci model of NHIE was used
[18–20]. On postnatal day 7 (P7), rat pups (n5 99) were anesthe-
tized with inhaled 3% sevoﬂurane. The right common carotid artery
was permanently double-ligated using a 5.0 surgical silk and severed.
Pups were allowed to recover with their dams for 2 hours, and then
placed into a hypoxia chamber in a water bath maintained at 378C,
under a constant ﬂow of 1.5 l/minute humidiﬁed 8% oxygen/balance
nitrogen for 90 minutes. SHAM rat pups (n5 23) underwent anes-
thesia, incision, and exposure of the right common carotid artery
without ligature or hypoxia. At the end of the procedure, pups were
returned to their cage and allowed to recover for 48 hours.
Cell Preparation and Transplantation
HUCBC samples (30–50 ml) from healthy human donors were col-
lected, in compliance with the French law and after obtaining
written informed consent forms from the parents. The cord blood
cells were obtained from anonymous donations and 52% of the
donors were male newborns. Preparation of the mononuclear cell
fraction was performed by the Ficoll gradient technique (Amer-
sham, Freiburg, Germany, http://www.amershambioscience.com).
Blood samples were processed within 24 hours after collection.
Before cell transplantation, HUCBC were washed three times with
phosphate-buffered saline (PBS) then suspended in PBS (1 3 107
cells per 0.5 milliliter).
ECFC were isolated as previously described from HUCBC [21].
Before cell transplantation, ECFC were starved overnight in endo-
thelial basal medium-2/with 2% fetal calf serum, washed three
times with PBS then suspended in PBS (5 3 105 cells per 0.5
milliliter).
Experimental Groups
Forty-eight hours after the surgical procedure, HI pups were ran-
domly allocated to three groups. Control pups (n5 35) were intra-
peritoneally injected with saline solution (500 ml) and the other
interventional animal groups either with HUCBC (1 3 107/500 ml,
n5 21) or ECFC (5 3 105/500 ml, n5 43). SHAM pups (n5 23)
were intraperitoneally injected with saline solution (500 ml).
Before cell or saline injections, pups were brieﬂy anesthetized
with 3% sevoﬂurane inhalation.
Neurological Assessment
Neurological assessment was performed at 14 days and 8 weeks
after HI.
Elevated Plus Maze Test. The elevated plus maze (EPM) test
was performed on P21 (n5 10/group) to evaluate animal anxi-
ety as previously described [22]. The EPM apparatus consists
of two open arms (50 3 10 3 1 cm) and two closed arms (50
3 10 3 40 cm) crossing on a common central platform (10 3
10 cm) forming a plus shape, elevated to 50 cm above the
ﬂoor. The anxiety-related behaviors of each animal were video-
recorded for a period of 5 minutes and analyzed with the Etho-
Vision XT7 (Noldus Information Technology, Leesburg, Virginia,
Figure 1. Experimental protocol. Abbreviations: ECFC, endothelial
colony-forming cells; HUCBC, human umbilical cord blood cells; P7,
postnatal day 7; SPECT, single photon emission computed
tomography.
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http://www.noldus.com). Brieﬂy, the rat was placed on the
central platform with its head facing an open arm. The arm
entry was deﬁned as all four paws into an open or a closed
arm. The total time each animal spent in any different section
of the maze (open arms, central platform, and closed arms)
was recorded. Results were expressed as mean6 SD percent
of “open arms entries” (OAE ratio, number of OAE divided by
the sum of entries in both open and closed arms), percent of
“closed arms entries” (CAE ratio, number of CAE divided by the
sum of entries in both open and closed arms), percent of
“open arms time” (OAT%, time spent in open arms divided by
the sum of time spent in both closed and open arms) and per-
cent of “closed arms time” (CAT%, time spent in closed arms
divided by the sum of time spent in both closed and open
arms). The animal’s natural tendency is to stay in closed spaces
because of its unconditioned fear for open spaces and height.
Open Field Test. At 8 weeks, each rat (n5 10 in each group)
was placed in an empty open ﬁeld (OF; 100 3 100 cm) and
allowed to freely explore the arena for 5 minutes. General loco-
motor behavior (total distance moved and velocity of movement)
was analyzed with EthoVision XT 7.
Novel Object Recognition Test. At 8 weeks, the animal’s explor-
atory behavior and its nonspatial learning and memory capacities
were assessed with novel object recognition test [23, 24]. Brieﬂy,
the rat (n5 10/group) was placed in an open apparatus (100 3
100 cm). Each animal’s journey was video-recorded and analyzed
with the EthoVision XT7 software. The day before the test, animals
received a habituation session of 30 minutes in the OF. On the
testing day, each rat completed four 3-minute sessions (intertrial
interval of 30 minutes). During the ﬁrst three sessions, the rat was
allowed to explore the arena, which contained two identical
objects. Total exploration time of the two objects was noted. For
the fourth session, one of the original objects was replaced by a
novel, different-shaped object, then each rat was returned to the
arena and was allowed to explore both objects (novel1 familiar)
for 3 minutes. The “object exploration” was considered when the
rat sniffed at the novel object within a 1 cm-distance or touched
the novel object with its nose. The time spent on each object
exploration was video-recorded and a discrimination ratio was cal-
culated (time spent to explore the novel object compared with
the total exploration time). The latency period to the ﬁrst explora-
tion of the novel object was also measured.
Morris Water Maze Test. Spatial learning and memory per-
formance were evaluated 8 weeks after HI lesion with the Morris
water maze (MWM) test (n5 10/group) as previously described
by Li et al. [25]. The MWM consists of a black circular pool virtually
divided in four equal quadrants located in a well-lit white room
with several spatial cues. Two centimeters beneath the water sur-
face and hidden from the rat’s view was a black circular platform.
(a) Spatial Acquisition Test. Training on spatial version of the
MWM was carried out over ﬁve consecutive days. On each day,
rats received four training trials in which the hidden platform was
left at the same place. The mean latency time to ﬁnd the platform
was measured for individual animals on each day as a learning
score. A different starting location was used in each trial, which
consisted of a swim followed by a 30-seconds platform rest. Rats
that did not ﬁnd the platform within 60 seconds were guided to it
by the experimenter.
(b) Reference Memory Test (Probe Trial). To assess long-term
memory, 24 hours after the ﬁnal trial, the platform was removed
from its ﬁxed location and the time spent in the target quadrant
over 60 seconds was measured.
Histologic and Immunohistochemistry Assessment
Animals were deeply anesthetized 7 days and 12 weeks after HI
with a lethal dose of pentobarbital (Clin Midy, Gentilly, France)
and rat brains were ﬁxed by trans-cardiac perfusion with 4%
phosphate-buffered paraformaldehyde (PFA) (Sigma-Aldrich,
Saint-Quentin Fallavier, France, http://www.sigmaaldrich.com).
After decapitation, the brain was removed from the skull and
post-ﬁxed for 24 hours in 4% PFA at 48C and was successively cryo-
preserved, snap-frozen, and stocked at 2808C. Frozen sections
were cut with a sliding microtome (CM1900, Leica, France SA,
http://www.leicabiosystems.com) and stored at 2808C. All sec-
tions were examined using a light and ﬂuorescent microscope
(Eclipse TE 2000-U, Nikon France SA, https://www.nikoninstru-
ments.com) equipped with a digital camera (DXM1200, Nikon
France SA) and an image analyzer (Lucia 5.0 software, Nikon
France SA). Histologic analysis was performed in 5–10 ﬁelds at the
cortical level of ipsilateral hemisphere and in the corresponding
location within contralateral hemisphere.
TUNEL Staining. Apoptotic cells were detected on 8 lm-thick
sections 7 days after injury by terminal deoxynucleotidyl
transferase-mediated 20-deoxyuridine 50-triphosphate nick-end
labeling (TUNEL) as previously described [26]. Only cells containing
apoptotic bodies are referred to as apoptotic cells. TUNEL positive
cells were counted under high-power microscope and expressed
as number of positive cells per square mm section.
Immunoﬂuorescent Staining. After nonspeciﬁc protein binding
blocking, slices were incubated (1/100, 2 hours, 48C) with the pri-
mary antibody (eNOS: 610297, BD Pharmingen, http://www.
bdbiosciences.com; NeuN: MAB377, Millipore, http://www.
merckmillipore.com; glial ﬁbrillary acidic protein, GFAP: M0761,
Dako, http://www.agilent.com) and were incubated secondary
antibodies. Cerebral vessel density (eNOS), neuronal survival
(NeuN), and astrogliosis (GFAP) are expressed as ipsilateral-to-
contralateral (i/c) ratio.
Immunohistochemistry. After endogen peroxydase activity
blocking and nonspeciﬁc protein binding blocking, sections were
incubated with mouse monoclonal anti-iNOS (1/100, 4 hours, BD
Pharmingen, 610297) and then incubated with the biotinylated
secondary antibody and visualized with 3,30-diaminobenzidine
(Thermoﬁscher, http://www.thermoﬁsher.com). Neuroinﬂamma-
tion is expressed as i/c ratio.
Single Photon Emission Computed Tomography
Radiotracers. Hexamethylpropyleneamine oxime kit (HMPAO,
Cerestab, General Electrics, Velizy-Villacoublay, France, http://
www.gehealthcare.com) was radiolabeled with fresh [99mTc]TcO–4
pertechnetate solution (500 MBq/1 ml) following the manufac-
turer’s instructions.
SPECT Data Acquisition. Seven days (P14) and 12 weeks after
HI insult, 20 MBq of [99mTc]Tc-HMPAO were injected through the
tail vein to assess cerebral blood ﬂow (CBF). Thirty minutes after
[99mTc]Tc-HMPAO injection, the animals were anesthetized with
Grandvuillemin, Garrigue, Ramdani et al. 1989
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1.5% sevoﬂurane and a cerebral SPECT/CT imaging was acquired
for 20 minutes (NanoSPECT/CT1 camera, Bioscan Europe Ltd.,
Paris, France).
SPECT Image Analysis. Images analysis was performed using
the 3D-ROI module part of InVivoScope software v2.0p4 (InviCRO,
Boston, https://www.invicro.com). Two volumes of interest (VOI)
were drawn over right (ipsilateral) and left (contralateral) cerebral
hemisphere for each animal in the axial section. Radioactivity
inside each VOI was quantiﬁed and corrected by the tissue volume
(MBq/mm3).We then calculated the i/c ratios (i/c, %). Image color
scales were normalized in order to illustrate CBF.
Statistical Analysis
Values were reported as mean6 SD unless otherwise indicated.
Physiological parameters were analyzed by unpaired t test. TUNEL
and immunoassaying data were tested for normality and were
compared with unpaired t test with Bonferroni correction for post
hoc intergroup comparisons. Behavioral and morphological out-
comes were compared between the groups using one-way analy-
sis of variance (ANOVA) followed by post hoc Bonferroni test.
Statistical analyses were performed with Prism software v5.03
(GraphPad Software, La Jolla, CA). A p value <.05 was considered
statistically signiﬁcant.
RESULTS
Survival rate: Survival rate after hypoxic-ischemic injury was 96%.
Locomotor behavior: To analyze locomotor behavior, OF activity
was performed at W8 in all experiment groups. Physical abilities
were similar in all groups (data not shown).
Neurological Assessment
HUCBC or ECFC Administration Equally Rescues Hypoxic-
Ischemic-Induced Short-Term Anxiety-Like Behavior Abnormal-
ities. The EPM test was performed on day P21 (n5 10/group).
The animal’s natural tendency is to stay in enclosed spaces, as was
the case with the SHAM group (91% of time spent in closed
arms). After HI injury, we observed a higher OAE ratio in the Con-
trol group compared with the SHAM group (OAE ratio, Control:
0.5686 0.08, SHAM: 0.2906 0.06; p< .05, n5 10, Fig. 2A) and a
higher percent of time in the open arms (OAT%, Control:
0.3576 0.1, SHAM: 0.0916 0.02, p< .05, n5 10, Fig. 2B). After
cellular therapy, we observed a signiﬁcant decrease in OAT ratio in
the HUCBC (0.0916 0.04, p< .05, n5 10) and ECFC groups
(0.0946 0.02, p< .05, n5 10) compared with the Control group
(Fig. 2B). There was no signiﬁcant difference between HUCBC,
ECFC, and SHAM animals.
HUCBC or ECFC Administration Equally Rescues Hypoxic-
Ischemic-Induced Long-Term Cognitive Deﬁcits. Morris Water
Maze Test. Control rats showed signiﬁcant spatial and learning
memory deﬁcits 8 weeks after HI as compared with SHAM rats.
(a) Spatial acquisition test (Fig. 3A): During the ﬁve training days,
the mean escape latencies to ﬁnd the platform in the HUCBC and
ECFC groups were signiﬁcantly shorter than in Control rats
(HUCBC: 29.16 6.6 seconds; ECFC: 25.86 7.2 seconds; Control:
44.66 3.1 seconds, n5 10 in each group, HUCBC vs. Control p <
.01; ECFC vs. Control p< .05). There were no signiﬁcant differen-
ces between the HUCBC, ECFC, and SHAM groups. (b) Reference
memory test (probe trial, Fig. 3B): Twenty-four hours after the last
training session, the time spent in the target quadrant (without
the platform) was measured. The SHAM, HUCBC, and ECFC groups
showed longer time spent in the target quadrant than Control
rats (SHAM vs. Control, p < .01; ECFC and HUCBC vs. Control,
p< .05) There was no difference between the ECFC, HUCBC, and
SHAM groups.
Novel Object Recognition Test. HI resulted in cognitive deﬁcit
involving nonspatial working memory and exploratory capacities
during the novel object recognition test, with a discrimination
ratio signiﬁcantly reduced in the Control group compared with
the SHAM group, (respectively, 0.556 0.1 and 0.926 0.03;
p< .05; n5 10/group, Fig. 4A). HUCBC and ECFC administration
signiﬁcantly increased exploratory and memory performance
compared with the Control group, with a higher discrimination
ratio (HUCBC: 0.886 0.02, p< .05; n5 10; ECFC: 0.896 0.03,
p< .05; n5 10, Fig. 4A). The mean escape latency to ﬁrst explora-
tion of the novel object was signiﬁcantly increased in the Control
group compared with the SHAM group (respectively 24.06 3.2
seconds and 8.316 2.2 seconds, p< .01, n5 10 in each group,
Fig. 4B) and was reduced in the HUCBC (11.286 1.8 seconds,
p< .01, n5 10, Fig. 4B) and ECFC (10.156 2.6 seconds, p< .05,
n5 10, Fig. 4B) groups. There was no difference between the
ECFC, HUCBC, and SHAM groups.
Figure 2. Evaluation of HUCBC or ECFC administration on anxiety-like
behavior measured by the elevated plus maze test at post-natal day 21.
(A): Percent of entries in open arms and in closed arms. (B): Percent of
time spent in open arms and in closed arms. (mean6SD; *, p< .05 com-
pared with Control; n5 10 in each group). Abbreviations: ECFC, endothe-
lial colony-forming cells; HUCBC, human umbilical cord blood cells.
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Histological and Immunochemical Assessment
HUCBC or ECFC Administration Decreased Apoptosis and Neu-
roinﬂammation Activation 7 Days After Neonatal HI. Seven
days post-HI, the HUCBC group revealed a signiﬁcantly lower corti-
cal neuroinﬂammation than the Control group (HUCBC vs. Con-
trol: 0.96 0.15 vs. 1.66 0.34; p5 .038; n5 5 per group, Fig. 5A).
The ECFC group revealed a trend to a lower neuroinﬂammation in
the ipsilateral cortex than the Control group but this difference
was not statistically signiﬁcant (ECFC vs. Control; 1.16 0.11 vs.
1.66 0.34; p5 .08, n5 5 per group, Fig. 5A).
Similarly, 7 days after HI, apoptotic cell number (Fig. 5B) was
signiﬁcantly lower in the HUCBC (5.56 1.2 cells/mm2; p5 .005,
n5 6) and ECFC groups (3.26 1.3 cells/mm2, p5 .006, n5 6)
than in the Control group (57.56 2.1 cells/mm2, n5 6)
HUCBC and ECFC Administration Equally Improved Early and
Late Neuronal Survival and Prevented the Formation of Astro-
cytic Scar. Neuronal survival: HI induced a signiﬁcant and
extended decrease of NeuN-immunopositive cells in the ipsilateral
hemisphere 7 days (0.996 0.08 vs. 0.806 0.07 in the SHAM and
Control groups respectively, p5 .026, n5 4 in each group, Fig.
6Aa, 6Ac) and 12 weeks after HI insult (0.996 0.15 vs. 0.746 0.1
in the SHAM and Control groups respectively, p5 .025, n5 4/
group, Fig. 6Ab, 6Ad).
Seven days after HI (Fig. 6Aa, 6Ac), NeuN-positive cells i/c
ratios were signiﬁcantly increased in the HUCBC (0.956 0.03,
p5 .0094, n5 4) and ECFC (0.906 0.05, p 5 .043, n5 4) groups
in comparison with the Control group.
Twelve weeks after HI (Fig. 6Ab, 6Ad), NeuN-positive cells i/c
ratios were still signiﬁcantly increased in the HUCBC group
(0.986 0.13, p5 .022, n5 4) and in the ECFC group (1.096 0.11,
p< .001; n5 4) in comparison with the Control group.
Figure 4. Evaluation of HUCBC and ECFC administration on Novel
Object Recognition test at post-natal 8 weeks. (A): Discrimination
ratio. (B): The mean escape latency to ﬁrst exploration of the novel
object. (mean6 SD; *, p < .05 compared with Control, **, p < .01
compared with Control; n5 10 in each group; one-way analysis of
variance followed by post hoc Bonferroni test). Abbreviations: ECFC,
endothelial colony-forming cells; HUCBC, human umbilical cord
blood cells.
Figure 3. Evaluation of cognitive function with the Morris water
maze test at post-natal 8 weeks. (A): Spatial acquisition test (Train-
ing sessions). (B): Reference memory test (day 6). (mean6 SD; *, p
< .05 compared with Control; **, p < .01 compared with Control;
n5 10 in each group; one-way analysis of variance followed by post
hoc Bonferroni test). Abbreviations: ECFC, endothelial colony-
forming cells; HUCBC, human umbilical cord blood cells.
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No Difference was Observed Between the SHAM, ECFC, and
HUCBC Groups 7 Days and 12 Weeks After HI. Astrogliosis: HI
induced a signiﬁcant and extended increase in astrogliosis,
expressed as i/c GFAP ratio, 7 days (0.826 20 vs. 1.596 0.12 in
the SHAM and Control groups respectively, p< .001, n5 5/group,
Fig. 6Ba, 6Bc) and 12 weeks after HI (0.986 0.24 vs. 3.536 0.9 in
the SHAM and Control groups respectively, p5 .004, n5 5/group,
Fig. 6Bb, 6Bd).
Seven days after insult (Fig. 6Ba, 6Bc), no signiﬁcant decrease
in astrogliosis was observed in the ECFC and HUCBC groups com-
pared with the Control group; whereas at W12 (Fig. 6Bb, 6Bd) we
observed a huge delayed decrease in astrogliosis in the ECFC
(0.966 0.23, p< .001, n5 5) and HUCBC (1.246 0.63, p< .05,
n5 5) groups compared with the Control group. No difference
was observed between the SHAM, ECFC, and HUCBC at W12.
HUCBC and ECFC Administration Both Resulted in an Early and
Sustained Increase in Cerebral Capillary Density, from Day 7 to
12 Weeks After Neonatal HI. In comparison with SHAM ani-
mals, HI was associated with a signiﬁcant reduction in cerebral
capillary density (i/c ratios) 7 days (0.976 0.03 vs. 0.736 0.04 in
SHAM and Control animals respectively, p< .001, n5 4/group,
Fig. 6Ca, 6Cc) and 12 weeks after HI insult (0.986 0.05 vs.
0.766 0.08 in SHAM and Control animals respectively, p5 .0014,
n5 4/group, Fig. 6Cb, 6Cd).
Seven Days After HI. cerebral capillary density was signiﬁ-
cantly higher in the HUCBC (1.006 0.06; p< .001; n5 5) group
and in the ECFC (1.096 0.08; p< .001; n5 6) group in compari-
son with the Control group. No difference was observed between
the SHAM, ECFC, and HUCBC groups. (Fig. 6Ca, 6Cc).
Twelve Weeks After HI. cerebral capillary density was signiﬁ-
cantly higher in the HUCBC (0.936 0.11; p5 .034, n5 6) group
and in the ECFC (1.026 0.08; p< .001, n5 6) group in compari-
son with the Control group. No difference was observed between
the SHAM, ECFC, and HUCBC groups (Fig. 6Cb, 6Cd).
Single Photon Emission Computed Tomography
Cerebral Blood Flow. Although no signiﬁcant difference was
found between conditions at P14, at W12 we observed in the
Control group a signiﬁcant decrease in CBF i/c ratios (77%6 2%,
n5 5) compared with the SHAM (99%6 3%, n5 5, p5 .019)
group and a signiﬁcant improvement in the HUCBC (95%6 2%,
p5 .017, n5 5) and ECFC (96%6 2%, p5 .014, n5 7) groups
compared with the Control group (Fig. 7).
DISCUSSION
Using a rat neonatal model of brain HI, we demonstrated that
HUCBC or ECFC administration similarly (a) limited cellular apopto-
sis, neuroinﬂammation, and astrocytic reaction, (b) restored cere-
bral capillary density, and (c) improved neuronal cell survival.
Long-term CBF and neurologic functions were deﬁnitively
improved as well.
Administration of HUCBC after neonatal cerebral HI in rats lim-
its the severity of brain injury and improves long-term neurologic
functions. Meier et al. were the ﬁrst to describe improved neuro-
logic functions in rats with neonatal cerebral HI after intraperito-
neal infusion of HUCBC (1 3 107 HUCB cells), 24 hours after
cerebral injury [7], and a preservation of somatosensory functions
in the ipsilateral hemisphere at P48 [27]. These effects have been
demonstrated in studies using different doses, administration
route, or administration timing of HUCBC after neonatal cerebral
insult [4–6, 28, 29]. Yasuhara et al. have shown improved motor
coordination as early as the 7th day after intravenous administra-
tion of low doses of HUCBC (1.53 104) [4]. Pimentel-Coelho dem-
onstrated that intraperitoneal injection of 23 106 HUCBC 3 hours
after the ischemic episode improved sensorimotor reﬂexes up to
10 days after injection. Most of these effects were associated with
decreased neuroinﬂammation and less apoptosis reaction [6, 30].
The mechanism by which HUCBC do limit brain injury is unclear.
Figure 5. Effects of HUCBC and ECFC administration on neuroinﬂammation (A) and apoptosis (B) 7 days after neonatal HI. (A): Representa-
tive photographs of iNOS immunohistochemistry in ipsilateral cortical brain section of Control (Aa), HUCBC (Ab), and ECFC (Ac) groups. (Ad):
Quantiﬁcation of iNOS immunopositive cells (ipsilateral/contralateral ratio), Scale bar: 40 mm. (B): Representative photographs of TUNEL
immunohistochemistry in ipsilateral cortical brain section of Control (Ba), HUCBC (Bb), and ECFC (Bc) groups. (Bd): quantiﬁcation of apoptotic
cells in the ipsilateral hemisphere. (mean6 SD; *, p< .05 compared with Control, **, p < .005 compared with Control; n5 5–6 in each
group; unpaired t test followed by post-hoc Bonferroni test). Abbreviations: ECFC, endothelial colony-forming cells; HUCBC, human umbilical
cord blood cells.
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Figure 6. Effects of HUCBC and ECFC administration on neuronal survival (A), astrogliosis (B), and capillary density (C) 7 days (a, c) and 12
weeks (b, d) after neonatal HI. Representative NeuN immunoﬂuorescence (red) at P14 (Aa) and W12 (Ac), Representative glial ﬁbrillary acidic
protein (GFAP) immunoﬂuorescence (green) at P14 (Ba) and W12 (Bc) and Representative eNOS immunoﬂuorescence (red) at P14 (Ca) and
W12 (Cc). Ipsilateral/contralateral ratio of NeuN-immunopositive cells at P14 (Ab) and W12 (Ad), ipsilateral/contralateral ratio of GFAP-
immunopositive cells at P14 (Bb) and W12 (Bd) and ipsilateral/contralateral ratio of eNOS-immunopositive cells at P14 (Cb) and W12 (Cd),
(mean6 SD; *, p < .05 compared with Control; **, p < .01 compared with Control, n55 in each group; unpaired t test followed by post hoc
Bonferroni test; scale bars5 20 mm). Abbreviations: ECFC, endothelial colony-forming cells; HUCBC, human umbilical cord blood cells.
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Cord blood contains different cell types with various functions
including mesenchymal cells, stem cells, progenitor cells, immune
cells (T-regulatory lymphocytes), and endothelial progenitor cells
which contribute to the neuroprotective effects. It has been pro-
posed that such effects result from in situ trophic/growth factors
release rather than from engraftment process [4, 6, 31], and stud-
ies found a limited number, or an absence of HUCBC in the injured
brain [4, 5, 7, 28]. Our ﬁndings provide further evidence on the
neuroprotective effects of HUCBC which sustain in adulthood.
The relevant ﬁndings of this study concern the signiﬁcant neu-
roprotective effects of ECFC administration after neonatal cerebral
HI, which have never been evaluated as cell therapy for neonatal
cerebral HI. ECFC are considered to be the relevant endothelial
progenitors due to their speciﬁc vasculogenic activity [11, 12]. We
previously showed that intravenous administration of ECFC con-
tributed to vascular recovery, limited tissue injury after hind limb
ischemia, and transient cerebral ischemia in adult rodents [14, 15,
32–35]. In all these models, ECFC administration was associated
with a decrease in apoptosis, a growth factor release enhance-
ment and a neovascularization stimulation.
Beneﬁcial effects of the administration of ECFC or HUCBC 3
days after cerebral HI in pups sustained in adulthood. Com-
pared with the Control group, ECFC and HUCBC administration
limited neuronal death, neuroinﬂammation and preserved
capillary density. We observed that cell therapy did not pre-
vent early glial cell proliferation, supposed to be protective,
but prevent delayed glial scar, reinforcing the hypothesis of a
temporary astroglial border that could limit ischemia to sur-
rounding tissues [36]. The effects of astrogliosis and microglia
on inﬂammation and oxidative stress reactions are debated
[37, 38], but a sustained microglial activation has been shown
to affect tissue integrity after ischemic injury through secreting
cytotoxic cytokines and free radicals [39–43].
We originally used mSPECT/CT imaging to follow-up brain
metabolism after cerebral HI from neonatal period to adulthood.
Brain perfusion is a critical parameter of cerebral tissue physiol-
ogy; maintenance of brain metabolism is ﬁnely tuned and needs a
constant provision of oxygen and glucose. Cerebral SPECT/CT
imaging showed a huge decrease in brain perfusion in Control rats
compared with the SHAM group at the adult stage (W12). These
alterations were associated with signiﬁcant impaired neurologic
functions and brain damages. Although no difference was
observed on day 7 after cerebral HI, adult HUCBC- or ECFC-treated
animals recovered brain metabolism and perfusion with less
extended brain damages and better neurological functions. Patho-
physiological processes including cell activity and cell proliferation,
tissue inﬂammation or regenerative processes may maintain tis-
sue metabolism and explain unchanged brain perfusion soon after
cerebral HI as observed in adult cerebral HI models [44]. All of
these ﬁndings make CBF as evaluated by SPECT/CT imaging a reli-
able tool to assess long-term consequences of neonatal HI and
the effects of experimental therapies.
The current study provides further evidence on the neuropro-
tective effects of HUCBC and ECFC after neonatal cerebral HI in
the rat. The experimental design included heterologous cell ther-
apy which questions the reliability of the model. However, some
evidence argues for the effectiveness of these cells. Neuroprotec-
tive effects of cord blood cells have been demonstrated in
Figure 7. Effects of HUCBC and ECFC administration on cerebral blood ﬂow (CBF) SPECT/CT 2 weeks and 12 weeks after hypoxia-ischemia.
(A): Brain representative tomographic images of 99mTc-HMPAO SPECT/CT assessing CBF 2 weeks (top row) and 12 weeks (bottom row) after
hypoxia-ischemia. (B): Quantiﬁcation of 99mTc-HMPAO activity in ischemic hemisphere (% of contralateral activity) 2 weeks (black bars) and
12 weeks (gray bars) after hypoxia-ischemia (mean6 SD; *, p < .05 compared with Control; n5 4–5 in each group; one-way analysis of var-
iance followed by post-hoc Bonferroni test). Abbreviations: ECFC, endothelial colony-forming cells; HMPAO, hexamethylpropyleneamine
oxime; HUCBC, human umbilical cord blood cells.
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immunodeﬁcient rodents [4, 45] and in a model of NHIE in lamb
after autologous administration of cord blood cells [46]. We did
not investigate the effects of hypothermia as used in clinical prac-
tice because our aim was to compare the effects of both HUCBC
and ECFC. The strength of our study was to investigate long-term
consequences of HUCBC and ECFC administration in a model of
neonatal cerebral HI using histologic, neurologic and SPECT imag-
ing tools. We found similar long-term neuroprotective effects
between both cell therapies which underlines the robustness of
cell therapies as therapeutic candidate for neonatal HI.
Clinical Implications
Caution is required when extrapolating our ﬁndings to infants
since current ﬁndings were observed in a speciﬁc experimental
model; but evidence argues for their potential relevance for NHIE.
The Rice-Vannucci model is considered a reference for studying
neonatal HI brain, since cortical maturity at 7 days post-delivery
in rats is similar to that of human newborns [19, 47]. We
observed, as previously reported [4, 5, 7, 16, 28, 29], that neona-
tal cerebral HI induced long-term neurofunctional and cognitive
deﬁcits with signiﬁcant impaired spatial and nonspatial memory
skills and behavior disorders in stress conditions, as can be seen
in children born with NHIE. The rat model is a valuable model for
studying pathophysiological mechanisms of NHIE and for evaluat-
ing the efﬁcacy and tolerance of cellular therapies. Our ﬁndings
and previous studies provide sufﬁcient data on the effectiveness
and the safety of using these cells in NHIE conditions [48–50].
NHIE is the second cause of neonatal death worldwide [51]
and is associated with high risk of long-term neurocognitive dis-
abilities in surviving infants. Therapeutic hypothermia, which is
the only protective therapy proposed in such a situation, has lim-
ited neuroprotective effects [1–3, 52, 53]. Combined therapies are
currently evaluated, out of which cell therapy using HUCBC has
promising potential neuroprotective effects. HUCBC are easily and
immediately available at the patient’s bedside just after birth.
Recently, in only one study, HUCBC administrations have been
shown to be feasible and well tolerated in newborns with severe
NHIE [54]. Using ECFC from cord blood is more debated. Their use
in clinical practice remains tricky since ECFC are allogeneic and
take several days to be produced. We have characterized cord
blood stem cells of neonates with neonatal asphyxia and com-
pared them with those from healthy newborn infants (NEOCORD,
NCT01284673). We observed that neonatal asphyxia seemed to
enrich cord blood stem cell content, with a higher quantity of
endothelial progenitor cells found in cord blood of asphyxiated
neonates (unpublished data). All these arguments conﬁrm our
choice to establish and set up a clinical study (NEOSTEM,
NCT02881970). Three other studies are ongoing (NCT01506258,
NCT02256618, NCT02605018) and the neonatal physician com-
munity has placed much hope in these strategies.
CONCLUSION
In the current study, we reported that a single HUCBC or ECFC
administration after neonatal cerebral HI in rat equally limited glial
cell proliferation, prevented apoptosis and neuronal loss and
improved capillary growth, CBF using mSPECT/CT imaging, and
neurologic functions up to young adulthood. Our ﬁndings provide
further evidence on the effectiveness and tolerability of HUCBC as
the potential candidate for clinical HI cell therapy.
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